Animal Health

Pharmaceutical-grade excellence transforming veterinary medicine. Brains Bio's Animal Health division applies our EU-GMP manufacturing platform and regulatory expertise to capture first-mover advantages in the emerging $1.1 billion veterinary cannabinoid market. Leveraging existing pharmaceutical infrastructure for exponential returns while maintaining the same quality standards that define our human health programs.

First-Mover Advantage.

Rising pet healthcare spending, consumer preference for natural therapeutics, and progressive regulatory frameworks are fueling unprecedented growth in veterinary cannabinoids. As pet owners increasingly demand pharmaceutical-grade solutions for their animals' chronic conditions, our EU-GMP capabilities create insurmountable competitive advantages in a market where quality standards will define long-term winners.

Projected Value Distribution

Scientific Foundation: Proven Therapeutic Potential

Companion animals possess endocannabinoid systems functionally similar to humans, making them physiologically responsive to cannabinoid therapeutics. Clinical evidence demonstrates efficacy across key therapeutic areas:

Canine: Osteoarthritis management with improved mobility scores, epilepsy reduction as adjunct therapy, and anxiety disorder treatment.
Feline: Stress-related behavioral modification, inflammatory dermatological conditions, and chronic pain management.
Equine: Post-exercise inflammation reduction, performance recovery acceleration, and mobility support for aging horses.

Dual-Path Commercialization Strategy

Veterinary Nutraceuticals: Premium over-the-counter solutions for anxiety, mobility, skin health, and digestive wellness. Distribution through veterinary clinics, specialty pet retailers, and targeted e-commerce platforms, emphasizing pharmaceutical-grade quality differentiation.
Prescription Veterinary Medicines: Co-developed therapeutic medicines with established veterinary pharmaceutical companies, targeting regulated applications in progressive markets including the United States, Brazil, Australia, and Europe where regulatory frameworks enable prescription cannabinoid therapies.

Synergistic Platform Expansion Amplifying Returns

Animal Health creates compound value by leveraging existing pharmaceutical infrastructure while expanding addressable markets. Veterinary programs utilize shared EU-GMP manufacturing capacity, regulatory expertise, and clinical development capabilities, maximizing returns on existing investments while creating new revenue streams that reinforce our core platform advantages.

By applying human pharmaceutical standards to veterinary applications, Brains Bio is positioned to lead market transformation while creating sustainable competitive advantages.

Competitive Advantages

Pharmaceutical-Grade Manufacturing

Certified APIs ensure batch-to-batch consistency and safety profiles that pet CBD companies cannot replicate, enabling premium positioning and veterinary professional confidence.

Regulatory Expertise

Human pharmaceutical regulatory experience accelerates veterinary submissions while reducing development risks and time-to-market across multiple jurisdictions.

Advanced Formulations

Advanced delivery systems including palatability-enhanced tinctures, functional soft chews, targeted topicals, and breakthrough transdermal applications designed for optimal absorption and compliance.

Global Partnerships

Established relationships across Latin America, Oceania, and Europe enabling rapid market entry, localized manufacturing partnerships, and regulatory pathway acceleration.

Jas Kalsi

An experienced Chartered Professional Accountant with over 30 years of experience in providing personal and corporate taxation, corporate restructuring, financing, public offering and human resources management services. Kalsi is the Chief Financial Officer for Brains Bioceutical Corp., a global manufacturer of naturally-sourced active pharmaceutical ingredients (APIs). In this role, Kalsi is responsible for overseeing and managing the fiscal health of the group, implementing best practices with respect to finance, accounting and internal controls, obtaining funding, providing recommendations on mergers and acquisitions and working collaboratively with the CEO and Board of Directors on strategy. In addition, Kalsi will be responsible to regulatory entities and authorities, including any security exchange commissions.

Kalsi was an audit partner at KPMG focusing on small, medium and large private, government sector and public audit clients. He was the Human Resource Manager in charge of recruiting, staff development and training, and a member of KPMG’s Professional Practice Group. Subsequent to KPMG, Kalsi was the Chief Financial Officer / Chief Executive Officer of a variety of private companies including 6.5 years with a pharmaceutical fulfillment provider and API developer.

Kalsi has a proven track record in hiring top-level senior executives, restructuring companies to minimize tax and maximize cash flows, raising financing and creating a cohesive culture.

Kalsi has a passion for wellness and has created several initiatives and partnered with several leading-edge individuals to help people create and enjoy the best versions of themselves. He sees the use cannabinoids as a major tool to facilitate one’s optimum lifestyle.

With the team and infrastructure in place, Brains Bioceutical has quickly become an industry leader in both the nutraceutical and pharmaceutical cannabinoid industries, with several clinical trials and academic studies underway evaluating the efficacy of cannabinoids to treat major diseases. Under Kalsi’s leadership, Brains Bioceutical has already established market dominance, as it is the only company in the world to sell bulk API commercially around the world, supporting both the pharmaceutical and wellness sectors. With ambitious plans to expand Brains Bioceutical into a global biotech company specializing in cannabinoid health and wellness solutions, Kalsi is pioneering a new frontier in medicinal and wellness solutions across the world.

Animal Health

First-Mover Advantage.

Projected Value Distribution

Scientific Foundation: Proven Therapeutic Potential

Dual-Path Commercialization Strategy

Synergistic Platform Expansion Amplifying Returns

Competitive Advantages

Contact Us

General Inquiries:

Animal Health

First-Mover Advantage.

Projected Value Distribution

Scientific Foundation: Proven Therapeutic Potential

Dual-Path Commercialization Strategy

Synergistic Platform Expansion Amplifying Returns

Competitive Advantages

Contact Us

General Inquiries:

Jas Kalsi

Chief Financial Officer

Jennifer Archibald

Chief Financial Officer

Barinder Bhullar

Senior Vice President, Corporate Affairs

William Purves

Chief Commercial Officer

Gurdeep Bains

VP of Business Development

Jorja’s Story

A father’s journey to saving his daughter’s life

Dr. Mike Bowen

Dr. Jack Taunton

Dr. Sharon Gurm

Dr. David Putrino

Dr. Gerry Ramogida

Norma Sebestyen

Dean Billington

COO

Terry O’Regan

President

Rick Brar

CEO and Chairman